PLATINUM-RESISTANT OVARIAN CANCER
Clinical trials for PLATINUM-RESISTANT OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT OVARIAN CANCER trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to prevent deadly bowel blockages in ovarian cancer
Disease control CompletedThis completed phase 2 trial tested whether the drug cediranib, given with chemotherapy, is safe for women with advanced ovarian cancer who are at risk of bowel obstruction. 30 participants received the combination. The study focused on whether the treatment caused serious bowel …
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE2 • Sponsor: Prof Gordon Jayson • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental COM902 drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug combo aims to outsmart Platinum-Resistant ovarian cancer
Disease control CompletedThis study tests a new drug called ZN-c3 (azenosertib), either alone or combined with niraparib, in 117 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find safe doses and see if the drugs can shrink tumors. It is an early-stage trial, s…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo shows promise for resistant ovarian cancer
Disease control CompletedThis study tested a combination of two drugs, pamiparib and surufatinib, in 29 women with ovarian cancer that stopped responding to platinum chemotherapy and had previously taken PARP inhibitors. The goal was to see if the combo could control the cancer for at least 6 months. The…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo shows promise for hard-to-treat ovarian cancer
Disease control CompletedThis study tested a combination of two drugs, apatinib and etoposide, in 35 women with ovarian cancer that had stopped responding to platinum-based chemotherapy. The goal was to see if the combination could shrink tumors or slow disease progression. Participants took the drugs by…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo shows promise in early trial
Disease control CompletedThis early-phase study tested a new drug called SL-172154 combined with either of two standard chemotherapies in 86 people with ovarian cancer that had stopped responding to platinum-based treatment. The main goals were to check safety and find the best dose. Researchers also loo…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1 • Sponsor: Shattuck Labs, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug combo shows promise against resistant ovarian cancer
Disease control CompletedThis Phase 2 trial tested whether adding afuresertib (an AKT inhibitor) to standard paclitaxel chemotherapy helps control platinum-resistant ovarian cancer better than paclitaxel alone. 150 women with this difficult-to-treat cancer participated. The study measured how long the ca…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Jun 26, 2026 15:45 UTC